WALTHAM, Mass .– (BUSINESS WIRE) – Sobi, an international biopharmaceutical company that transforms lives
of people affected by rare diseases, today announced the publication of
data demonstrating the continuing burden of respiratory failure
infection due to respiratory syncytial virus (RSV) in preterm infants
Babies in the USA
The data represent the results of the SENTINEL study1, where 46
US hospitals collected observational data on preterm infants
infants born between 29 and 35 weeks of gestation who did not receive
immunoprophylaxis for RSV and were subsequently hospitalized for RSV
during the seasons of RSV 2014-2015 or 2015-2016 (approximately
until April). A total of 1,378 infants with RSV acquired in the community
hospitalization were evaluated; of these, 45% were admitted to the
intensive care unit (ICU), 19% required invasive mechanical ventilation
(IMV), and two babies died. In the subset of earlier and younger
premature infants (born between 29 and 32 weeks of gestation and less than 3 months
elderly when hospitalized for RSV), the burden was more severe, with 69%
these babies hospitalized in the ICU and 41% needing IMV; the two deaths
both occurred in this younger and earlier preterm group.
The study also found that among premature infants who were discharged
after birth during the RSV season (November 1 to March 31,
this analysis) and subsequently readmitted due to RSV infection, 46%
were reintroduced within 30 days and 82% were readmitted within 60 days.
For the subgroup of premature and younger preterm infants, the hospital
The cost incurred in the two seasons was US $ 122,301.
The results were similar in 2014-2015 and 2015-2016
indicate the continued burden of the serious illness
premature infants born in the USA and in the health system. SENTINEL1
represents the largest study ever conducted in the USA of preterm infants
infants hospitalized with laboratory-confirmed severe RSV disease. O
data were published in the American Journal of Perinatology in April
2019 and are available online
via open access.
"RSV is the most common cause of childhood hospitalization in the United States.
Despite notable advances in the care of preterm infants in the past
two decades, this study demonstrates that RSV causes
morbidity among premature infants who do not receive RSV
immunoprophylaxis. This morbidity translates into a substantial
in the health system, "said Evan J. Anderson, MD, senior author on
the role and Associate Professor of Pediatrics and Medicine in Emory
Faculty of Medicine of the University.
About Respiratory Syncytial Virus (RSV)
Syncytial virus (RSV) is the most common cause of respiratory failure
(ITRIs) in infants and young children worldwide
the most common cause of infant hospitalization in premature infants
children are at increased risk of being hospitalized for an ITRI
of RSV infection than children born at term. Currently there are no
specific treatment approved for RSV, once contracted, in addition to
supportive care while the disease continues its course, causing
availability of SRR prophylaxis as a critical public health priority.1
About Sobi in North America
As an American Affiliate
of the international biopharmaceutical company Sobi ™, our team is committed
to Sobi's vision of providing sustainable access to innovative therapies
and transform the lives of people affected by rare diseases. We bring
something rare for rare diseases – a belief in the strength of focus, the
power of agility and the potential of the people dedicated to
serving. Our product portfolio includes various approved treatments,
focused on immunology and genetics / metabolism. With North America
headquarters in the Boston area, Canadian headquarters in Toronto
representatives from the sales, medical and market access areas
covering North America, our growing team has a proven track record of
business excellence. More information is available at www.sobi-northamerica.com.
For more information about Sobi, visit www.sobi.com.
1. Adamko DJ, Friesen M. Why does respiratory syncytial virus appear
to cause asthma? Journal of Allergy and Clinical Immunology.
2012; 130 (1): 101-102. doi: 101016 / j.jaci.2012.05.024.